Gill, A., et al. “The Discovery of Novel Protein Kinase Inhibitors by Using Fragment-Based High-Throughput X-ray Crystallography.” ChemBioChem 6, no. 3 2005: 506–512. DOI: 10.1002/cbic.200400188.

Gill, A., et al. “The Discovery of Novel Protein Kinase Inhibitors by Using Fragment-Based High-Throughput X-ray Crystallography.” ChemBioChem 6, no. 3 2005: 506–512. DOI: 10.1002/cbic.200400188.

Gill, A.L., et al. “Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation.” Journal of Medicinal Chemistry 48, no. 2 2005: 414–426. DOI: 10.1021/jm049575n.

Gill, A.L., et al. “Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation.” Journal of Medicinal Chemistry 48, no. 2 2005: 414–426. DOI: 10.1021/jm049575n.

Hartshorn, M.J., et al. “Fragment-Based Lead Discovery Using X-ray Crystallography.” Journal of Medicinal Chemistry 48, no. 2 2005: 403–413. DOI: 10.1021/jm0495778.

Hartshorn, M.J., et al. “Fragment-Based Lead Discovery Using X-ray Crystallography.” Journal of Medicinal Chemistry 48, no. 2 2005: 403–413. DOI: 10.1021/jm0495778.

Kirton, S.B., et al. “Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.” Proteins: Structure, Function, and Bioinformatics 58, no. 4 2005: 836–844. DOI: 10.1002/prot.20389.

Kirton, S.B., et al. “Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.” Proteins: Structure, Function, and Bioinformatics 58, no. 4 2005: 836–844. DOI: 10.1002/prot.20389.

Miles Congreve, Christopher W. Murray and Tom L. Blundell. “Keynote review: Structural biology and drug discovery.” Drug Discovery Today 10, no. 13 2005: 895–907. DOI: 10.1016/S1359-6446(05)03484-7.

Miles Congreve, Christopher W. Murray and Tom L. Blundell. “Keynote review: Structural biology and drug discovery.” Drug Discovery Today 10, no. 13 2005: 895–907. DOI: 10.1016/S1359-6446(05)03484-7.

Robin A.E. Carr, Miles Congreve, Christopher W. Murray, David C. Rees. “Fragment-based lead discovery: leads by design.” Drug Discovery Today 10, no. 14 2005: 987–992. DOI: 10.1016/S1359-6446(05)03511-7.

Robin A.E. Carr, Miles Congreve, Christopher W. Murray, David C. Rees. “Fragment-based lead discovery: leads by design.” Drug Discovery Today 10, no. 14 2005: 987–992. DOI: 10.1016/S1359-6446(05)03511-7.

Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.

Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.